| 摘要 |
PURPOSE: To provide permanent healing of malaria in the erythrocytic phase, i.e., the clinical phase and prevent the relapse by using a combination of an interferon with a substance having the antimalarial activities. CONSTITUTION: A combination of an interferon, preferably interferon-γand a substance having antimalarial activities, e.g. 9-aminoacridines (e.g. mepacrine), 4-aminoquinolines (e.g. chloroquine), 8-aminoquinolines (e.g. primaquine), biguanides having dihydrofolate reductase inhibiting effects (e.g. cycloguanil), diaminopyrimidines (e.g. pyrimethamine), a quinine salt, a sulfonamide, a sulfanilamide, an antibiotic substance (e.g. tetracyline) and a sulfone is used for producing a pharmaceutical preparation for treating malaria infection in the erythrocytic clinical phase. |
